Back to top

Research Daily

Mark Vickery

Top Stock Reports for NextEra, Raytheon & Bristol-Myers


Trades from $3

Monday, October 11, 2021

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including NextEra Energy, Inc. (NEE), Raytheon Technologies Corp. (RTX), and Bristol-Myers Squibb Co. (BMY). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of NextEra have outperformed the Zacks Electric Power industry in the year to date period (+5.5% vs. +2.2%). The Zacks analyst believes that a well-chalked capital investment plan, natural gas pipeline projects, robust renewable backlog, addition of renewable generation assets, and adequate liquidity bode well for the long term.

The company currently has a lot of renewable projects in its backlog. The company has ample liquidity to meet current debt obligations. Strict regulations, inherent risk related to operating nuclear generation facilities and unfavorable supply costs are some of the major headwinds for the company though.

(You can read the full research report on NextEra here >>>)

Raytheon shares have gained +53.7% over the past year against the Zacks Defense Equipment industry’s gain of +39.9%. The Zacks analyst believes that merger related synergies and solid order growth are likely to aid the company’s revenues going forward.

It continues to receive ample orders from the Pentagon due to a wide range of combat-proven defense products that it offers. The company continues to see growth trends in its military section. Impact of the ongoing pandemic has been weighing on commercial aerospace. A dismal outlook in the near term remain is another major concern for the company.

(You can read the full research report on Raytheon here >>>)

Shares of Bristol-Myers have lost -7.2% over the past six months against the Zacks Biomedical and Genetics industry’s loss of -4.4%, however, things seem to be improving for the company. The Zacks analyst believes that strong sales of drugs like Opdivo, Revlimid and Eliquis are likely to continue driving the top line.

The label expansion of Opdivo into indications of lung cancer and gastric cancer should propel its sales and offset the decline from recent setbacks. The approval of new drugs has added a new stream of revenues, which should lead to incremental revenue growth ahead. The company, however, has been facing stiff competition in the immuno-oncology space. Pipeline setbacks are an added concern.

(You can read the full research report on Bristol-Myers here >>>)

Other noteworthy reports we are featuring today include Petrobras (PBR), The Williams Companies, Inc. (WMB) and Occidental Petroleum Corp. (OXY).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Featured Reports

New Upgrades

New Downgrades